Baillie Gifford & CO Royalty Pharma PLC Transaction History
Baillie Gifford & CO
- $131 Billion
- Q3 2024
A detailed history of Baillie Gifford & CO transactions in Royalty Pharma PLC stock. As of the latest transaction made, Baillie Gifford & CO holds 16,122,491 shares of RPRX stock, worth $407 Million. This represents 0.35% of its overall portfolio holdings.
Number of Shares
16,122,491
Previous 16,352,759
1.41%
Holding current value
$407 Million
Previous $431 Million
5.77%
% of portfolio
0.35%
Previous 0.34%
Shares
11 transactions
Others Institutions Holding RPRX
# of Institutions
413Shares Held
283MCall Options Held
578KPut Options Held
47.5K-
Morgan Stanley New York, NY41.1MShares$1.04 Billion0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA37.6MShares$948 Million0.02% of portfolio
-
Black Rock Inc. New York, NY23MShares$581 Million0.01% of portfolio
-
Viking Global Investors LP12.1MShares$305 Million1.32% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA11.9MShares$300 Million0.62% of portfolio
About Royalty Pharma plc
- Ticker RPRX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 437,139,008
- Market Cap $11B
- Description
- Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic i...